Phase I study of transfer of effector memory T cells (Tem) following allogeneic stem cell transplantation. Short title- Transfer of Tem (ToTem)
同种异体干细胞移植后效应记忆 T 细胞 (Tem) 转移的 I 期研究。
基本信息
- 批准号:MR/R025436/1
- 负责人:
- 金额:$ 133.61万
- 依托单位:
- 依托单位国家:英国
- 项目类别:Research Grant
- 财政年份:2018
- 资助国家:英国
- 起止时间:2018 至 无数据
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
Healthy bone marrow produces blood cells, including those of the immune system that fight infections. All these blood cells originate from stem cells. When cancer affects a patient's bone marrow, it can no longer carry out its normal function. In order to restore healthy blood cell production and to fight the cancer, some patients are given healthy stem cells from a donor's bone marrow. Although bone marrow transplants can cure many patients, they can have serious side effects. One of these serious side effects, that affects about half of patients, is 'graft versus host disease' (GVHD). This happens because the bone marrow contains donor immune cells (the 'graft') that see the patient's healthy cells (the 'host') as foreign and attacks them. It mainly affects the tissues of the skin, the liver and the gut and can be life threatening.There are ways of preventing GVHD by using drugs that dampen down (suppress) the donor's immune cells in the patient's body, therefore stopping them from overreacting and attacking their body. However, the use of these immune supressing drugs has a major drawback because the immune system becomes weaker and cannot fight infections as well. These infections are sometimes very severe and can lead to patients dying.We have been working on new ways to prevent the donor's immune system causing GVHD in the patient's body without weakening it so much that it cannot fight infections as well. We have developed a new, simple way to take additional infection-fighting immune cells from the same donor's blood. When these are given to patients, they may help fight infections but not overreact and cause GVHD. If this works, it could be widely used at many hospitals across the country. This is because it uses equipment that is already used routinely by most bone marrow transplant centres.Therefore, this clinical trial aims to find out if giving patients these additional infection-fighting immune cells from the donor will reduce their chance of getting an infection without causing GVHD. Patients undergoing a bone marrow transplant will be asked if they want to give their consent to be part of the study. For these patients, we will give additional donor immune cells about one month after the transplant. They will also receive the standard GVHD prevention treatment. Different doses of the donor immune cells will be given to individual patients to work out which dose is best. All patients will be closely monitored for signs of GVHD or infection. They will also have blood tests to determine how well and quickly their immune systems recover. If the trial shows a possible benefit to patients, we will plan to extend the study to a larger number of patients. This will provide the necessary proof whether the treatment works in patients needing a bone marrow transplant.
健康的骨髓产生血细胞,包括那些抵抗感染的免疫系统。所有这些血细胞都来源于干细胞。当癌症影响患者的骨髓时,它就不能再发挥正常的功能。为了恢复健康的血细胞生产和对抗癌症,一些患者从捐赠者的骨髓中获得健康的干细胞。虽然骨髓移植可以治愈许多患者,但它们可能有严重的副作用。这些严重的副作用之一,影响了大约一半的患者,是“移植物抗宿主病”(GVHD)。这是因为骨髓中含有供体免疫细胞(“移植物”),这些细胞将患者的健康细胞(“宿主”)视为外来细胞并攻击它们。它主要影响皮肤、肝脏和肠道组织,可能危及生命。有一些方法可以通过使用药物来预防GVHD,这些药物可以抑制患者体内的供体免疫细胞,从而阻止它们过度反应和攻击他们的身体。然而,使用这些免疫抑制药物有一个主要缺点,因为免疫系统变得更弱,也不能抵抗感染。这些感染有时非常严重,可能导致患者死亡。我们一直在研究新的方法,以防止供体的免疫系统在患者体内引起GVHD,而不会削弱它,使其无法抵抗感染。我们已经开发出一种新的,简单的方法,从同一个捐赠者的血液中提取额外的抗感染免疫细胞。当这些给患者使用时,它们可能有助于对抗感染,但不会反应过度并导致GVHD。如果成功,它可以在全国许多医院广泛使用。这是因为它使用的设备已经被大多数骨髓移植中心常规使用。因此,这项临床试验的目的是找出是否给患者这些额外的抗感染免疫细胞从捐赠者将减少他们得到感染的机会,而不引起GVHD。将询问接受骨髓移植的患者是否愿意同意参与研究。对于这些患者,我们将在移植后约一个月给予额外的供体免疫细胞。他们还将接受标准的GVHD预防治疗。不同剂量的供体免疫细胞将被给予个体患者,以确定哪种剂量最好。将密切监测所有患者的GVHD或感染体征。他们还将进行血液测试,以确定他们的免疫系统恢复得有多好和多快。如果试验显示可能对患者有益,我们将计划将研究扩展到更多患者。这将为需要骨髓移植的患者提供必要的证据。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ronjon Chakraverty其他文献
Graft-Versus-Host Disease Induces Immune Dysregulation through Irreversible Damage to Specialized Immune-Interacting Fibroblastic Stromal Cells in Secondary Lymphoid Organs
- DOI:
10.1182/blood-2022-167650 - 发表时间:
2022-11-15 - 期刊:
- 影响因子:
- 作者:
Leolene Carrington;Shovik Bandyopadhyay;Katlyn Lederer;Samantha Kelly;Ashley Vanderbeck;Gloria Jih;Frederick Allen;Daniela Gómez Atria;Anneka Allman;Eric Perkey;Kai Tan;Norbert Pardi;Burkhard Ludewig;Ronjon Chakraverty;Ivan Maillard - 通讯作者:
Ivan Maillard
Natural History of Epstein-Barr Virus Replication and Viral Load Dynamics after Alemtuzumab-Based Allogeneic Stem Cell Transplantation
- DOI:
10.1016/j.jtct.2021.04.020 - 发表时间:
2021-08-01 - 期刊:
- 影响因子:
- 作者:
Maria A.V. Marzolini;Andrew J. Wilson;Emilie Sanchez;Ben Carpenter;Ronjon Chakraverty;Rachael Hough;Panos Kottaridis;Emma C. Morris;Kirsty J. Thomson;Karl S. Peggs - 通讯作者:
Karl S. Peggs
Measure selection for an electronic patient-reported outcome (ePRO) system for CAR T-cell therapy patients: a modified Delphi consensus study
嵌合抗原受体T细胞(CAR T细胞)疗法患者电子患者报告结局(ePRO)系统的测量指标选择:一项改良的德尔菲共识研究
- DOI:
10.1016/j.eclinm.2025.103256 - 发表时间:
2025-06-01 - 期刊:
- 影响因子:10.000
- 作者:
Sarah E. Hughes;Foram Khatsuria;Christel McMullan;Karen L. Shaw;Anita Walker;Francesca Kinsella;David Burns;Olalekan L. Aiyegbusi;Elin Haf Davies;John Ansell;Evelyn Chakera;Charles Craddock;Alastair Denniston;Rebecca Lloyd;Paul Ferguson;Ronjon Chakraverty;Melanie Calvert - 通讯作者:
Melanie Calvert
CMV-Specific T-Cell Therapy Improves Immune Reconstitution Following Unrelated Donor HSCT: Results of a Randomized Controlled Trial
- DOI:
10.1016/j.bbmt.2013.12.048 - 发表时间:
2014-02-01 - 期刊:
- 影响因子:
- 作者:
Frederick Chen;Andrew Peniket;Eleni Tholouli;Adrian Bloor;Ronjon Chakraverty;David Marks;Antonio Pagliuca;Nigel Russell;Kirsty Thomson;Heather Beard;Katy Newton;Mohammad Raeiszadeh;Simon Thomas;Paul Moss;Karl S. Peggs - 通讯作者:
Karl S. Peggs
Ruxolitinib in Patients With Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of Efficacy and Safety From the Phase III REACH3 Study
- DOI:
10.1182/blood-2023-172590 - 发表时间:
2023-11-02 - 期刊:
- 影响因子:
- 作者:
Robert Zeiser;Domenico Russo;Ron Ram;Shahrukh K Hashmi;Ronjon Chakraverty;Jan Moritz Middeke;Maurizio Musso;Sebastian Giebel;Ant Uzay;Peter Langmuir;Nada Hamad;Xuechan Li;Maanasa Gowda;Tommaso Stefanelli;Stephanie J. Lee;Takanori Teshima;Franco Locatelli - 通讯作者:
Franco Locatelli
Ronjon Chakraverty的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ronjon Chakraverty', 18)}}的其他基金
The role of endogenous glucocorticoids in regulating dendritic cell function in vivo
内源性糖皮质激素在体内调节树突状细胞功能的作用
- 批准号:
G0601183/1 - 财政年份:2008
- 资助金额:
$ 133.61万 - 项目类别:
Research Grant
相似国自然基金
Incentive and governance schenism study of corporate green washing behavior in China: Based on an integiated view of econfiguration of environmental authority and decoupling logic
- 批准号:
- 批准年份:2024
- 资助金额:万元
- 项目类别:外国学者研究基金项目
酶响应的中性粒细胞外泌体载药体系在眼眶骨缺损修复中的作用及机制研究
- 批准号:82371102
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
CBP/p300-HADH轴在基础胰岛素分泌调节中的作用和机制研究
- 批准号:82370798
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
糖尿病ED中成纤维细胞衰老调控内皮细胞线粒体稳态失衡的机制研究
- 批准号:82371634
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
Got2基因对浆细胞样树突状细胞功能的调控及其在系统性红斑狼疮疾病中的作用研究
- 批准号:82371801
- 批准年份:2023
- 资助金额:47.00 万元
- 项目类别:面上项目
Foxc2介导Syap1/Akt信号通路调控破骨/成骨细胞分化促进颞下颌关节骨关节炎的机制研究
- 批准号:82370979
- 批准年份:2023
- 资助金额:48.00 万元
- 项目类别:面上项目
含Re、Ru先进镍基单晶高温合金中TCP相成核—生长机理的原位动态研究
- 批准号:52301178
- 批准年份:2023
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
丁酸梭菌代谢物(如丁酸、苯乳酸)通过MYC-TYMS信号轴影响结直肠癌化疗敏感性的效应及其机制研究
- 批准号:82373139
- 批准年份:2023
- 资助金额:48.00 万元
- 项目类别:面上项目
胆固醇合成蛋白CYP51介导线粒体通透性转换诱发Th17/Treg细胞稳态失衡在舍格伦综合征中的作用机制研究
- 批准号:82370976
- 批准年份:2023
- 资助金额:48.00 万元
- 项目类别:面上项目
α-酮戊二酸调控ACMSD介导犬尿氨酸通路代谢重编程在年龄相关性听力损失中的作用及机制研究
- 批准号:82371150
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
相似海外基金
Project Verdant – Zero Emission Crew Transfer Vessel (ZE-CTV), Phase 1 Conversion Feasibility Study
Verdant 项目 — 零排放船员转移船 (ZE-CTV),第一阶段转换可行性研究
- 批准号:
10063150 - 财政年份:2023
- 资助金额:
$ 133.61万 - 项目类别:
Collaborative R&D
Multilineage DAmFRET to investigate AD/ADRD protein phase behavior in neural tissue models
多谱系 DAmFRET 研究神经组织模型中 AD/ADRD 蛋白相行为
- 批准号:
10583428 - 财政年份:2023
- 资助金额:
$ 133.61万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 133.61万 - 项目类别:
Intravital 2-photon imaging the integration of transplanted embryonic neurons in a mouse model of cerebral ischemia at the subacute phase
亚急性期脑缺血小鼠模型中移植胚胎神经元整合的活体 2 光子成像
- 批准号:
10704648 - 财政年份:2022
- 资助金额:
$ 133.61万 - 项目类别:
Nuclear import receptors as modifiers of TDP-43 phase transition and toxicity in FTD/ALS
核输入受体作为 TDP-43 相变和 FTD/ALS 毒性的调节剂
- 批准号:
10608681 - 财政年份:2022
- 资助金额:
$ 133.61万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 133.61万 - 项目类别:
Phosphorylation as a site-specific regulatory mechanism of the liquid-liquid phase separation of TDP-43 low complexity domain.
磷酸化作为 TDP-43 低复杂性结构域液-液相分离的位点特异性调节机制。
- 批准号:
10620157 - 财政年份:2021
- 资助金额:
$ 133.61万 - 项目类别:
Phosphorylation as a site-specific regulatory mechanism of the liquid-liquid phase separation of TDP-43 low complexity domain.
磷酸化作为 TDP-43 低复杂性结构域液-液相分离的位点特异性调节机制。
- 批准号:
10401259 - 财政年份:2021
- 资助金额:
$ 133.61万 - 项目类别:
A phase I trial of AdKCNH2-G628S gene therapy for post-op atrial fibrillation
AdKCNH2-G628S 基因治疗术后房颤的 I 期试验
- 批准号:
10513931 - 财政年份:2021
- 资助金额:
$ 133.61万 - 项目类别:
Phase 1 Trial to Assess Safety and Immune Effects of Xenon Gas in Healthy Human Subjects
评估氙气对健康人体受试者的安全性和免疫影响的第一阶段试验
- 批准号:
10758938 - 财政年份:2021
- 资助金额:
$ 133.61万 - 项目类别: